RxDoctor Payments Data

James Felberg, MD

Hospitalist · Lubbock, TXNPI 1205853736

Payments from drug & device makers

$433in general payments, 2019–2025

Across 18 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$116
  • Sanofi-aventis U.S. LLC$105
  • AstraZeneca$60
  • EMD Serono, Inc.$57
  • Novartis$45
  • Viiv Healthcare Company$36
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer6$116
Sanofi-aventis U.S. LLC1$105
AstraZeneca(2 entities)3$60
EMD Serono, Inc.4$57
Novartis2$45
Viiv Healthcare Company1$36
Amgen1$15

How this compares

$433 in reported general payments places this provider in the 75th percentile of 1,284 hospitalist providers in Texas.

See all hospitalist providers in Texas

Medicare billing

Part B allowed, 2024
$39,875
Medicare patients
238
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hospitalist in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →